Outcome of patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT) has improved. To investigate if this improvement can be transposed to the ICU setting, we conducted a systematic review and meta-analysis to assess short-term mortality of critically ill allo-HSCT patients admitted to the ICU and to identify prognostic factors of mortality. Public-domain electronic databases, including Medline via PubMed and the Cochrane Library were searched. All full-text articles written-English studies published from 2006 to 2016, including allo-HSCT adults transferred to the ICU were included. Eighteen studies were selected, including 2342 patients. Overall estimated ICU mortality was 51.7%. Prognostic factors associated with an increased ICU mortality were mechanical ventilation (OR = 12.2, 95% CI = 6.2-23.7), vasopressors (OR = 6.3, 95% CI = 3.6-11.1), renal replacement therapy (OR = 4.2, 95% CI = 2.8-6.2), ICU admission for acute respiratory failure (OR = 2.2, 95% CI = 1.1-4.4), acute kidney injury (OR = 2.2, 95% CI = 1.3-4), and acute graftversus-host disease (OR = 1.6, 95% CI = 1.1-2.3). Factors associated with an increased ICU survival were a single-organ failure (OR = 0.2, 95% CI = 0.1-0.4), neurological failure (OR = 0.4, 95% CI = 0.2-0.8), and reduced-intensity conditioning regimens (OR = 0.7, 95% CI = 0.5-0.9). Septic shock, underlying malignancy, disease status, donor, and graft source did not impact prognosis. Outcome has improved, supporting the usefulness of ICU management. Organ failures at ICU admission, organ support requirement, and GVHD are the main prognostic factors.
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Introduction
Major advances have been made in the care of patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT) [1] [2] [3] [4] [5] , including advances in hematology, transplant procedures, and development of reducedintensity conditioning (RIC) regimens [6, 7] , resulting in improved outcome [8] . Decrease in overall mortality, nonrelapse mortality, relapse, severe graft-versus-host disease Registered on PROSPERO (http://www.crd.york.ac.uk/PROSPERO/, number 42016047307).
(GVHD), infections, and liver, kidney, and lung damages have been reported through the last decade [8] . However, allo-HSCT remains associated with significant mortality with 10-50% of patients requiring intensive care unit (ICU) management for a life-threatening complication [9] [10] [11] .
ICU admission of allo-HSCT patients has long been controversial. Studies from the nineties reported >90% mortality rates, and 100% when mechanical ventilation (MV) was required [12] .
Prognostic factors in mechanically ventilated transplant recipients were age, severity score at ICU admission, and time from transplant to intubation. No one survived with lung injury combined with either hemodynamic instability or hepatic and renal failure. Therefore, ICU was considered as futile and seriously debated. Meaningful improvements over time were reported in hematology patients (HP) admitted to the ICU [13] [14] [15] , due to major advances in ICU management, including acute respiratory failure (ARF) diagnostic and therapeutic approach and septic shock management [16] [17] [18] . However, whether these encouraging results can be applied to critically ill allo-HSCT patients is currently unknown. Allo-HSCT remains a poor prognostic factor in ICU HP [16] . Organ failures at ICU admission, organ support requirement [19] , and GVHD appeared as the main prognostic factors [20] [21] [22] [23] . Intensivists are increasingly asked to manage these patients [5] . Many unresolved issues remain, including the optimal ICU admission policy. Identification of robust prognostic factors associated with short-term mortality might be helpful for ICU admission policy and therapeutic decisions.
To investigate if the improvements reported in allo-HSCT patients can be transposed to the ICU setting, we conducted a systematic review and meta-analysis to assess short-term mortality of critically ill allo-HSCT patients admitted to the ICU and to identify prognostic factors of short-term mortality.
Materials and Methods
This systematic review and meta-analysis was reported following criteria set by the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement and PRISMA 2015 protocols (PRISMA-P) [24, 25] . This meta-analysis was registered on the international register PROSPERO (http://www.crd.york.ac.uk/PROSPERO/, number 42016047307).
Search strategy and eligibility assessment
Public-domain electronic databases, including Medline via PubMed and the Cochrane Library were searched by using Medical Subjects Headings and the appropriate corresponding keywords: "allogenic hematopoietic stem cell transplantation"; "critically ill HSCT recipients"; "stem cell transplant"; "risk factors"; "prognosis"; "prognostic factors"; "intensive care unit"; "ICU survival"; "outcome"; "mortality"; "organ failure"; and "mechanical ventilation". We searched registered trials for ongoing and recently completed trials, but none existed. The research was restricted to full-text articles written in English language, adult patients, published from 2006 to 2016, examining critically ill allo-HSCT patients transferred to the ICU. References cited in the articles of interest and published reviews were manually searched to find additional reports. The search was re-run immediately prior to analysis to ensure that the most current information was presented. Titles and abstracts were carefully checked and studies focusing on children, autologous SCT, case reports, and case studies were excluded, as well as abstracts not published as full manuscripts and publications with no primary endpoint reported. Duplicates were first removed from the search results. All remaining references were then analyzed. Two authors (CS and DM) independently determined studies that met the inclusion criteria outlined above. Any disagreements were resolved by discussion.
Study outcome
The aim of the meta-analysis was to evaluate short-term mortality of critically ill allo-HSCT in the ICU and to identify prognostic factors independently associated with short-term mortality, represented by ICU mortality. When ICU mortality was not available, in-hospital mortality was used.
Data extraction and quality assessment
Two authors (CS and DM) carried out data extraction independently, and secondly verified. Two other authors (MD and EL) validated the methodology and data selection. For each included studies, information was extracted as following, using a standardized pre-piloted form: study design; date of publication; inclusion period; number of patients; median age; conditioning regimen; donor type; GVHD; median time from allo-HSCT to ICU admission; organ support requirement; follow-up; and short-term outcome. For the meta-analysis, ICU mortality in several predefined subgroups was extracted, in order to test the prognostic impact of each potential prognostic factor, previously identified by the systematic literature review [11] . Quality assessment of the included studies included the number of patients included, median follow-up, and study design. However, all the studies were homogenous in term of methodology, all of them being retrospective and usually single-center with small-sample size cohorts, making standard scale or checklists inappropriate for bias assessment.
Statistical analysis
Systematic literature review identified all the prognostic factors published so far. Meta-analysis was used in order to determine the independent effect of the following variables on short-term mortality: requirement of MV; non-invasive ventilation (NIV); vasopressors; renal replacement therapy (RRT); number of organ failures (0-1 versus ≥2); year of ICU admission (<2004 versus ≥2004); time between allo-HSCT and ICU admission (<30 versus ≥30 days); admission for ARF; neurological cause; septic shock; bacterial infection; acute kidney injury (AKI), hepatic failure at ICU admission; comorbidity (Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) 0-2 versus ≥3) [26] ; underlying hematological malignancy (acute leukemia [27] versus others); disease status (complete remission versus stable or progressive disease); donor type (unrelated versus others); conditioning regimen (RIC versus myeloablative conditioning (MAC) regimen); graft source (peripheral stem cells versus bone marrow); and GHVD at ICU admission. ICU death was considered as an event. For each potential prognostic factor, the meta-analysis was attempted only if relevant data could be extracted from ≥3 trials. Some preplanned analysis could not be carried out due to insufficient reported variables.
Results were analyzed using Review Manager 5.1 (Cochrane Collaboration, Oxford, UK). The estimation of overall ICU mortality was calculated with 95% confidence interval (95% CI). The impact of all potential prognostic factors independently associated with ICU mortality was tested. The summary estimates of odds ratios (ORs) were calculated using the fixed-effects model and presented as forest plots after pooling. All estimates are presented as proportion with two-sided 95% CI. The pooled OR, symbolized by a solid diamond at the bottom of the forest plot, is the best estimate of the pooled outcome. When available, the multivariate-adjusted hazard ratios for ICU mortality with 95% CI were used, with combined OR. Publication bias was assessed by visually inspecting the funnel plots. Cochrane's chi 2 
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to assess inter-study heterogeneity. Statistically significant heterogeneity was considered if I 2 was >50% and chi 2 < 0.1, respectively. A p < 0.05 was considered as statistically significant. All meta-analyses were performed using the fixed-effects model (assuming the existence of heterogeneity). Random-effects model was used in case of significant heterogeneity.
Results

Study selection process
Study selection process is represented in Fig. 1 . Initial search yielded 828 potentially relevant citations. Those considered as irrelevant were excluded. Finally, 18 studies, with a total of 2342 patients, fulfilled our eligibility criteria and were included [20, 22, 23, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . All were retrospective. Sample size ranged from 25 to 497. In all, 16 out of 18 were monocentric.
Patients' characteristics
Characteristics of patients and studies are reported in Table S1 . Period of inclusion ranged from 1995 to 2013. ICU transfer rate ranged from 10 to 57%. Median age varied from 34 to 55 years. Median time between allo-HSCT and ICU transfer ranged from 10 to 149 days. The main allo-HSCT indication was acute myeloid leukemia, followed by acute lymphoblastic leukemia, myelodysplastic syndromes, lymphoma, and myeloma. Conditioning regimens were mainly MAC, considering period inclusion. Intra-familial human leukocyte antigen-compatible donors were used in 20-70%. The use of alternatives donors varied widely according to centers [43] . The most frequent ICU admission was ARF, followed by septic shock, neurological failure, and AKI. Eleven to 75% of patients presented with GVHD. The different organ supports required were MV in 32-100% of patients, NIV in 28-40%, vasopressors in 30-67%, and RRT in 4-48% of patients.
Overall ICU mortality
In the selected studies, the estimated overall ICU mortality of critically ill allo-HSCT patients admitted to the ICU was 51.7% (39-63.6%). Mortality decreased over time with estimated overall ICU mortality of 63.9% <2004 (58.2-67.7%) and 37.2% (33.4-40.4%) ≥2004, respectively (p < 0.01).
ICU mortality prognostic factors
Influence of organ failures at ICU admission
Patients requiring MV had an increased ICU mortality, with OR = 12.1 (95% CI = 6.2-23.7, p < 0.001; Fig. 2 ). Analysis of combined OR, extracted from studies reporting ICU mortality adjusted to MV in multivariate analysis, confirmed the negative impact of MV on outcome with OR = 3.2 (95% CI = 2.1-5, p < 0.001; Figure S1 ). Vasopressors were also associated with a significantly higher ICU mortality, with OR = 6.3 (95% CI = 3.6-11.1, p < 0.001; Figure S2) . The use of RRT was also a poor prognostic factor, with OR = 4.2 (95% CI = 2.8-6.2, p < 0.001; Figure S3) , confirmed by the analysis of combined OR, with OR = 1.8 (95% CI = 1.4-2.3, p < 0.001; Figure S4 ). NIV did not impact prognosis, with OR = 1.48 (95% CI = 0.96-2.29, p = 0.08), but only a few studies reported data from patients who underwent NIV. ICU admission reason impacted ICU prognosis. Indeed, patients admitted to the ICU for ARF carried an unfavorable prognosis with OR = 2.2 (95% CI = 1.1-4.4, p = 0.03; Figure S5 ). Patients presenting to the ICU with AKI had an increased risk of ICU mortality with OR = 2.2 (95% CI = 1.3-4, p = 0.005; Figure S6 ). Hepatic failure tended to have a negative prognostic impact with OR = 1.8 (95% CI = 0.8-3.7, p = 0.13), although it might 
Influence of patients and transplant characteristics
Acute GVHD at ICU admission appeared as an unfavorable prognostic factor associated with ICU mortality, with OR = 1.6 (95% CI = 1.1-2.3, p = 0.01; Figure S8 ). Patients benefiting from RIC regimens had a favorable ICU outcome compared to patients receiving MAC, with OR = 0.7 (95% CI = 0.5-0.9, p = 0.01; Fig. 5 ). ICU outcome of patients undergoing allo-HSCT for acute leukemia did not differ from others malignancies (OR = 1.1, 95% CI = 0.8-1.5, p = 0.5; Figure S9 Figure S11 ). Short-term mortality did not differ according to donor type, with OR = 0.9 (95% CI = 0.7-1.3, p = 0.7; Figure S12 ), neither graft source with OR = 1.2 (95% CI = 0.8-1.8, p = 0.3; Figure S13 ).
Discussion
This meta-analysis, including 2342 patients, evaluated ICU mortality and prognostic factors associated with ICU mortality in critically ill adult allo-HSCT patients. Overall, estimated ICU mortality was 51.7%. We confirmed that mortality has decreased, compared to the 1990s' literature. These results are particularly encouraging, as results keep improving over time [20] . It demonstrates that improvements observed in allo-HSCT patients can be transposed to the ICU setting [8] and supports the use of ICU resources. It is to note that survival improved, whereas patients nowadays are older, with more comorbidities and more advanced diseases. We confirmed organ failures as independent prognostic factors on ICU mortality, including MV, vasopressors, and RRT requirement. We showed that ICU admission for ARF was an independent prognostic factor, whether MV was required or not, as already published in critically ill HP where ARF, MV, and NIV were associated with 43%, 60%, and 46% hospital mortality rates, respectively [16] . It indicates a need for developing better management strategies [44] . Along this line, standardized diagnostic approaches, non-invasive diagnostic strategies [45] , and ventilation strategies were recently developed, including NIV [46, 47] and high-flow nasal cannula oxygen Test for overall effects: Z = 5.77 (P < 0.00001) Fig. 4 Intensive care unit mortality of critically ill allogenic hematopoietic stem cell transplantation patients according to the number of organ failures (0-1 versus ≥2) (HFNCO) [48] . NIV did not impact prognosis, probably due to the lack of reported data. NIV, although controversial [49, 50] , might be interesting in allo-HSCT patients, frequently presenting with cardiac participation [51] . Randomized clinical trials are currently investigating the best ventilation strategy in HP. Results will need to be confirmed in allo-HSCT patients.
Vasopressor requirement was independently associated with increased ICU mortality. Septic shock in HP was associated with 45% mortality rates in recent publications [52] [53] [54] [55] , and up to 58% when vasopressors were required [16] . Septic shock management has considerably improved over the last decade, with early-goal-directed therapy [56] and Sepsis Campaign guidelines [17] . Microbiological documentation is crucial as the absence of diagnosis is a major prognostic factor [14] . It has to be outlined that septic shock and bacterial infection did not impact short-term prognostic, whereas vasopressors did. It enhances the role of early ICU admission, before vasopressor requirement stage.
Renal failure and RRT were independent predictors of ICU mortality. AKI is particularly relevant in allo-HSCT patients, who are at very high risk due to nephrotoxic drugs, combined with sepsis, engraftment syndrome, sinusoidal obstruction syndrome (SOS), and transplant-associatedthrombotic microangiopathy (TA-TMA) [30, 57, 58] . AKI adversely affects survival, gradually with severity, with hospital mortality of 46% in critically ill allo-HSCT patients [30] . These results are comparable with the 41% hospital mortality rate reported in critically ill HP with AKI, and 60% in those requiring RRT [16] . It can result in incomplete renal recovery and chronic kidney disease, prohibiting the fulfillment of complete therapeutic program. Once again, early ICU admission appears particularly relevant, hospital mortality increasing from 47% in Kidney disease Improving Global Outcomes grade 1 AKI to 83% in grade 3 AKI [30] .
Hepatic dysfunction represents a major diagnostic and therapeutic challenge [59] . Hepatic failure in allo-HSCT decreased over the last years, attributed to RIC, less frequent bacteremia, SOS, and hepatic GHVD [8] . However, in critically ill HP acute liver dysfunction was associated with 82% hospital mortality [16] . No literature is available in hepatic failure in ICU allo-HSCT patients, because it is under-reported and under-investigated, only a few patients benefiting from transjugular liver biopsy [60] . Our analysis was probably underpowered to demonstrate the prognostic impact of hepatic failure.
Interestingly, neurological dysfunction at ICU admission had a favorable impact on short-term outcome. It confirms the results of ICU HP with neurological failure who have a 33% hospital mortality rate [16] . It can easily be explained by frequent reversible causes, mainly due to hydroelectrolytic disorders and cyclosporine-associated posterior reversible encephalopathy syndrome [61] .
Overall, the number of organ failures appeared as a strong prognostic factor, patients with 0-1 organ failures carrying a better prognosis than patients with ≥2 organ failures. Severity scores at ICU admission, which have never been validated in allo-HSCT patients, could not been analyzed considering that each study analyzed different scores at different time points [22, 31, 32, 37, 39] . Our results reinforce the great importance of early ICU admission to avoid multi-organ failure requiring many organ supports. Early ICU admission is well documented in HP [16] , ARF setting, newly diagnosed AML, and septic shock [16, [62] [63] [64] [65] . It implies an accurate severity assessment in wards and a close collaboration between hematologists and intensivists [66] . Along this line, intermediate-care units located next to the ICU, as well as rapid response teams [66, 67] and high case-volume cancer-specialized ICU [53, 55] could be interesting.
Comorbidity may have an important effect on outcome. It is well documented in allo-HSCT patients [26, 68] and in critically ill HP where Charlson comorbidity index and poor performance status negatively impacted prognosis [16] . Hematologic and transplant characteristics, such as Fig. 5 Intensive care unit mortality of critically ill allogenic hematopoietic stem cell transplantation patients after reduced-intensity or myeloablative conditioning regimen underlying malignancy [27] , disease response, donor type, or graft source [69] did not impact short-term mortality, suggesting that they should not be used in the ICU transfer decision process. CR was associated with a better prognostic in one study in allo-HSCT patients [22] and in ICU HP [16] . Disease status was under-reported, resulting in underpowered analysis. Interestingly, we confirmed the better outcome in patients receiving RIC regimen, compared to MAC, as already demonstrated in two studies [22, 41] . It demonstrates that the favorable impact of RIC on prognosis can be transposed to the ICU setting [8] . Lastly, we confirmed acute GHVD as an unfavorable prognostic feature in the ICU [70] , as strongly suggested by recent data [20, 28, 31, 38, 39] . Whether these patients should be admitted to the ICU is very controversial [11] , particularly in patients with acute GVHD requiring MV [20] . Many potential prognostic factors deserve to be explored in future studies, as they represent unresolved issues and major challenges coming up. It includes the place of HFNCO [48] , the impact of invasive pulmonary aspergillosis [71] , rare complications such as TA-TMA [72] and SOS [59] , the impact of haplo-transplant [43] , second allo-HSCT [73] , and second ICU admission. No literature exploring these factors in allo-HSCT patients is available.
We acknowledge several limitations. First, available data are limited to observational, retrospective, single-center, small-sample cohorts. Second, there is a wide heterogeneity in patients, age, underlying malignancy, disease status, donor type, and transplantation procedures. Moreover, the admission period was wide, although our analysis was restricted to studies published after 2006 and did not reflect all recent improvements. ICU admission and discharge policies changed substantially thus limiting the conclusions that survival really improved overtime. Third, there are no consensual ICU admission criteria for these patients. It widely differs, according to center experience, hematologist involvement in the ICU, and case-volume effect [53, 55, 74] . Most of study centers had hematologists and intensivists available around the clock, which is not the case everywhere. Lastly, meta-analysis of prognostic variables carries particular difficulties. The major concern is the quality of the primary studies and the possibility of publication bias [75] . However, in the absence of prospective studies or large homogeneous retrospective cohorts, this meta-analysis may represent the best evidence supporting actual knowledge in allo-HSCT patients in the ICU. Summarizing actual knowledge, identifying data already robustly demonstrated, identifying major challenges coming up, and exploring all the potential prognostic factors, which deserved to be investigated represents a first step before designing upcoming studies. Lastly, these results may lead to practical implications, as no recommendations are available, guiding the decision of ICU admission, especially identifying patients that will not benefit from ICU admission.
ICU survival of critically ill adult allo-HSCT patients admitted to the ICU has improved over time, supporting the usefulness of ICU management in well-selected patients. This large meta-analysis confirms the unfavorable prognostic impact of organ failures at ICU admission, organ support requirement, and GVHD on ICU mortality. Conversely, RIC, ICU admission for neurological failure, and single-organ failure at ICU admission were associated with a better survival. A close collaboration between intensivists and hematologists, leading to early ICU admission, is crucial. Multicenter prospective studies are needed to confirm these results and to clarify optimal management in unresolved situations.
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